Browse the evidence

Short-term intensive insulin therapy can induce T2DM remission in newly diagnosed patients with high blood glucose levels (HbA1c ≥ 10% and FBG ≥ 11.1 mmol/L) by restoring beta-cell function.

If you were just diagnosed with Type 2 Diabetes and your blood sugar is very high, your doctor might suggest a short course of insulin. This isn't forever; it's used to quickly lower your blood sugar and give your pancreas a break so it can start working better on its own. This is most effective for people recently diagnosed.

The Blue Zones longevity paradigm is invalid because extreme longevity records in these regions are statistically associated with poverty, illiteracy, and clerical errors rather than lifestyle factors.

Do not rely on Blue Zone recommendations as a guaranteed path to longevity. The evidence suggests that the extreme longevity often cited in these regions is likely due to administrative errors and fraud rather than their lifestyle. Focus on verifiable health metrics and accurate data rather than geographic myths.

The Lipid Hypothesis, which demonized saturated fats and promoted high-carbohydrate diets, is flawed and has contributed to the global pandemic of chronic metabolic diseases.

Re-evaluate your intake of saturated fats. The paper suggests that saturated fats are essential for health and that the high carbohydrate intake promoted by the Lipid Hypothesis may be contributing to metabolic diseases. Consider reducing carbohydrates and incorporating healthy saturated fats.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) induce significant weight loss and metabolic improvement in patients with Bardet-Biedl syndrome (BBS), a genetic obesity syndrome previously resistant to standard pharmacotherapy.

If you have Bardet-Biedl Syndrome and struggle with severe obesity despite trying other medications, GLP-1 receptor agonists (like semaglutide or liraglutide) combined with dietary changes may be a viable treatment option. This case showed a 33% weight loss and normalized blood sugar, suggesting that genetic obesity is not necessarily resistant to these specific hormonal therapies.

In women, initial skeletal muscle size (leg fat-free mass and quadriceps CSA) is positively associated with the magnitude of muscle atrophy following 14 days of immobilization.

For women undergoing immobilization, having larger muscles prior to injury may be associated with greater absolute muscle loss. However, this finding is based on a small group and needs confirmation. Do not let this discourage building muscle; focus on proper rehabilitation.

Metabolic and bariatric surgery (MBS) improves depressive, anxiety, and non-normative eating symptoms, as well as attention, compared to nonsurgical controls, though evidence certainty is low to very low.

If you have obesity and struggle with depression, anxiety, or disordered eating, metabolic and bariatric surgery (MBS) may help improve these symptoms more than nonsurgical treatments. However, the evidence is not yet high-quality, and you should be aware that MBS might slightly increase the risk of substance use disorders or suicide in the long term (>2 years). Regular mental health monitoring is essential after surgery.

Metabolic and bariatric surgery (MBS) slightly increases the risk of substance use disorders and suicide deaths more than 2 years post-surgery compared to nonsurgical controls.

Be aware that while MBS improves mental health symptoms, it may slightly increase the risk of substance use disorders and suicide more than 2 years after surgery. Long-term mental health support and monitoring are essential to mitigate these risks.

Retatrutide, a triple-hormone receptor agonist (GLP-1/GIP/Glucagon), can cause intractable, secretory diarrhea and acute kidney injury, particularly when used off-label via unregulated online sources with unestablished dosing protocols.

If you are using retatrutide or similar GLP-1 agonists obtained from online sources, be aware that dosing is not standardized and risks are higher. Intractable diarrhea and kidney injury are serious potential side effects. Seek regulated medical care for weight loss management to ensure safe dosing and monitoring.

Higher baseline levels of Myostatin are associated with significant functional decline (Gait Speed and 6MWD) in older adults with sarcopenia, while inflammatory markers (IL-6, hsCRP) show less consistent or no correlation with functional decline.

While not yet a standard clinical test, high Myostatin levels may predict functional decline in sarcopenic older adults. In contrast, common inflammatory markers (CRP, IL-6) did not correlate with functional decline in this study, suggesting they may not be the primary drivers of functional loss in this population.

Vegan athletes may experience slower recovery from exercise-induced muscle damage (EIMD) compared to omnivores, characterized by greater delayed onset muscle soreness and reduced jump performance, likely due to lower protein and amino acid intake.

If you are vegan, pay close attention to your protein intake, especially around training. You may experience more muscle soreness and slower return of power (jump height) after intense workouts. Ensure you are consuming enough total protein and diverse plant sources to provide all essential amino acids for repair.

GLP-1 agonists (e.g., tirzepatide) and metformin show promise in improving asthma outcomes in obese patients by enhancing insulin sensitivity and reducing airway inflammation, though specific FDA approvals for obesity-associated asthma are lacking.

If you have asthma and obesity, discuss with your doctor whether metabolic treatments like GLP-1 agonists might help your asthma symptoms, especially if you have insulin resistance. While not yet approved specifically for asthma, they may improve lung function and reduce inflammation.

GLP-1 agonists like semaglutide may reduce the exposure (efficacy) of ALK tyrosine kinase inhibitors like alectinib due to delayed gastric emptying.

Be aware that taking semaglutide might reduce how much cancer medication your body absorbs. However, slow titration (starting low and going slow) may help mitigate this interaction.

GLP-1 analogs are widely used in Saudi Arabia for diabetes management and show some weight loss efficacy, but there is no trial data for their use in obesity-only patients in the country.

GLP-1 analogs are used in Saudi Arabia for diabetes, but there is no specific trial data for obesity-only patients. Use with caution and monitor weight loss.

Obesity in IBD patients is associated with altered pharmacokinetics of biological therapies, leading to faster drug clearance, lower trough concentrations, and potentially reduced treatment efficacy.

If you take biological injections for IBD and are obese, your body might process the drug faster than a lean person's, making it less effective. You should discuss this with your doctor. They might monitor your drug levels more closely or adjust your dose to ensure you get the full benefit of the treatment.

Sarcopenic obesity (high fat mass combined with low muscle mass and function) is a distinct and high-risk phenotype in chronic liver disease (CLD) and IBD, associated with worse prognosis, higher mortality, and increased surgical complications compared to obesity alone or sarcopenia alone.

For people with liver disease or IBD, being obese is risky, but losing muscle makes it much worse. This combination, called 'sarcopenic obesity,' leads to higher death rates and surgery complications. You need to check your muscle mass, not just your weight. If you are losing weight, make sure it's fat, not muscle.

Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.

Semaglutide 2.4mg weekly leads to ~15% weight loss. While it likely works partly by boosting metabolism (browning fat) via complex hormonal pathways seen in animals, the primary driver for you is reduced appetite. Do not rely on the 'browning' mechanism to explain your results; focus on the proven appetite suppression.

GLP-1 receptor agonists (GLP-1RAs) may reduce the severity of Obstructive Sleep Apnoea (OSA) as measured by the Apnoea-Hypopnoea Index (AHI), primarily through weight loss mechanisms, though evidence quality is currently low and results are conflicting.

If you have OSA and are considering GLP-1RAs (like semaglutide or liraglutide), expect a modest improvement in sleep breathing (AHI) rather than a cure. The benefit is largely tied to weight loss. Do not stop using your CPAP machine unless your doctor advises it, as CPAP is currently more effective. Be prepared for potential stomach side effects, which are common but often subside. The evidence is not yet strong enough to make this a standard first-line treatment for OSA alone.

Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.

Newer multi-incretin agonists (like tirzepatide) are showing superior improvements in blood sugar, weight, and blood pressure compared to single GLP-1RAs. While their specific impact on heart attacks and strokes is still being studied, they represent a promising next step for cardiovascular risk reduction in diabetes.

Resistance exercise-induced lactate accumulation may promote skeletal muscle hypertrophy through multiple mechanisms including lactate-stimulated testosterone production, histone lactylation, and activation of satellite cell pathways via GPR81/ERK1/2 signaling, although direct evidence in humans is currently insufficient.

While mechanical tension is king, incorporating training styles that generate high lactate (e.g., higher reps, shorter rest) may offer additional hypertrophic benefits via metabolic signaling. However, do not rely on this as a primary driver, as human evidence is currently weak compared to mechanical load.

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Controlled metabolic accelerators (CMAs) like HU6 induce weight loss via increased mitochondrial energy expenditure (uncoupling) rather than caloric restriction, resulting in fat loss while sparing skeletal muscle mass in patients with obesity-related HFpEF.

This paper describes a new class of drugs (CMAs) that burn fat by speeding up metabolism rather than restricting food. In early studies, this approach reduced fat mass significantly while keeping muscle mass stable, unlike diet or surgery which often weaken patients. This trial tests if this works for heart failure patients with obesity. It is not a lifestyle intervention but a pharmaceutical one requiring medical supervision.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

Human observational studies on MSG and obesity show inconsistent results, with some finding positive associations and others finding no association or inverse associations, largely due to measurement errors and confounding factors.

Human studies on MSG and weight are mixed. While animal studies suggest risks, human data is not conclusive. Reducing intake of processed foods with hidden MSG is a low-risk strategy for overall health.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.